Cerus Corp (NASDAQ:CERS)

CAPS Rating: 2 out of 5

The Company develops and commercializes novel, proprietary products and technologies within the fields of blood safety and immunotherapy that provides safer and more medical options to patients in areas of unmet medical need.


Player Avatar TMFBlacknGold (98.72) Submitted: 12/21/2012 9:16:40 AM : Underperform Start Price: $3.27 CERS Score: +24.27

Cerus recovered nicely from two horrible quarters (4Q11 and 1Q12) by dramatically slashing losses without increasing revenue. The improvement in efficiency is nice to see, but ultimately the company is still way over priced. With only $17 million in shareholders' equity and losses mounting every quarter there is little reason it should sport a market cap of $187 million. Underperform long term.

Featured Broker Partners